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Since the development of the third-generation aromatase inhibitors (AIs), anastrozole, letrozole and exemestane, these agents have
been the subject of intensive research to determine their optimal use in advanced breast cancer. Not only have they replaced
progestins in second-line therapy and challenged the role of tamoxifen in first-line, but there is also evidence for a lack of cross-
resistance between the steroidal and nonsteroidal AIs, meaning that they may be used in sequence to obtain prolonged clinical
benefit. Many questions remain, however, as to the best sequence of the two types of AIs and of the other available agents, including
tamoxifen and fulvestrant, in different patient groups.
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What is the optimal sequence for hormonal therapy in breast
cancer? Until recently, the antioestrogen tamoxifen was the only
agent approved for adjuvant therapy. At the time of relapse,
postmenopausal patients with tamoxifen-resistant disease (pro-
gressing during adjuvant tamoxifen or within 1 year from its
discontinuation) were generally offered an aromatase inhibitor
(AI), followed by a progestin (usually megestrol acetate) when they
further progressed. This paradigm needs to be reconsidered in
the light of recent developments following the early results of the
Arimidex, Tamoxifen Alone or in Combination (ATAC) study (The
ATAC Trialists Group, 2002), with anastrozole becoming an
alternative to tamoxifen in the early adjuvant setting (years 0–5).
Moreover, early results of the MA17 trial (Goss et al, 2003a) and of
the Intergroup Exemestane Study (Coombes et al, 2004) suggest
that a sequence of tamoxifen followed by an AI may be beneficial
in the early or in the extended adjuvant setting (years 5–10),
respectively.
Further results of ongoing adjuvant trials are eagerly awaited,
but it is likely that in the future an increasing number of patients
who present with advanced breast cancer will already have
received an AI (with or without tamoxifen) as part of their
adjuvant therapy. The remaining patients will have had tamoxifen
only, and a few will be hormone-therapy naı ¨ve. After taking
into account previous treatments, the choice of an appropriate
hormonal therapy should be based on efficacy and tolerability data
of the available agents.
Before trying to determine where each agent should fit in the
sequence of therapy, it is worth noting that the alternative strategy,
combination therapy, does not appear to provide advantages
over the use of single agents. The recently completed ATAC study
found that the combination of anastrozole and tamoxifen was no
more effective than either agent alone. There was a statistically
significant improvement in disease-free survival at 3 years for
anastrozole compared with tamoxifen (hazard ratio (HR) 0.83), but
not for combination therapy compared with tamoxifen (HR 1.02).
In women with oestrogen-receptor positive tumours, the HR was
0.78 in favour of anastrozole compared with tamoxifen or
combination therapy. The recently published Intergroup Exemes-
tane Study did not explore combined treatments, but its results
support the sequential use of tamoxifen and AIs. Switching to
exemestane after 2–3 years of tamoxifen therapy resulted in a
significant reduction in disease-free survival events (HR 0.68;
Po0.001) compared with continuing on tamoxifen (Coombes et al,
2004). Similarly, sequential use of letrozole given after 5 years of
tamoxifen showed improved disease-free survival vs placebo in the
MA17 trial (Goss et al, 2003a).
Given that the use of single agents appears preferable, should
tamoxifen or AIs be used as first-line treatment in a hormone-
therapy naive patient, or in a patient who has completed adjuvant
tamoxifen more than 12 months before relapse (i.e. in a potentially
tamoxifen-sensitive patient)? The improved efficacy (time to
progression) and side effect profile of AIs compared with
tamoxifen (Milla-Santos et al, 2000; Nabholtz et al, 2000; Dirix
et al, 2001; Mouridsen et al, 2001) suggest that these agents should
be used first. This is reinforced by the results of studies comparing
AIs and tamoxifen in the neoadjuvant setting (Eiermann et al,
2001; Ellis et al, 2001; Semiglazov et al, 2003; Tubiana-Hulin et al,
2003). AIs are also considered the agents of first choice for patients
with tamoxifen-resistant disease (i.e. those who progress during or
within 1 year from adjuvant tamoxifen).
A more problematic choice is faced for a patient who has already
received an AI as part of her adjuvant therapy. Is there a role for
further treatment with an AI in such a patient? The same question
arises at the time of second progression after treatment with AIs in
the advanced disease setting.
RATIONALE FOR SEQUENCING OF AIs
In both cases, the goal of continuing endocrine therapy for as long
as possible is to prolong the control of the disease and delay the
need for chemotherapy, thus also delaying its associated toxicity.
Based on structural differences and different mechanisms of action
among the AIs, a lack of cross-resistance between steroidal and
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of different AIs in the same patient during the course of her
disease.
The chemical structures of steroidal (e.g. exemestane and
formestane) and nonsteroidal (e.g. anastrozole and letrozole)
agents are illustrated in Figure 1. The steroidal inactivator,
exemestane, has a very similar structure to the androgen substrate
for aromatase, androstenedione (Figure 1); its covalent binding
to aromatase results in irreversible inactivation of the enzyme. By
contrast, nonsteroidal AIs bind to the haeme part of aromatase,
and the inhibition is reversible. It is uncertain, however, whether
this structural difference results in significant clinical differences.
Both steroidal and nonsteroidal AIs effectively reduce serum
oestrogen concentrations in postmenopausal patients. Intra-
tumoural aromatase may, however, be an important additional target
for inhibition (Brodie et al, 1999), and differences between the AIs
at this level cannot be excluded. Moreover, the partial androgen
activity of exemestane, which is lacking with the nonsteroidal AIs,
may also represent a difference relevant to sequencing. About 70–
80% of all breast cancers express the androgen receptor, and
androgens have been shown to have antiproliferative effects on
breast cancer cell lines (Ando et al, 2002).
Although the pharmacological and molecular bases for their lack
of cross-resistance need to be investigated further, the possibility
of successfully using steroidal and nonsteroidal AIs in sequence is
supported by clinical studies (Harper-Wynne and Coombes, 1999;
Lønning et al, 2000; Carlini et al, 2001; Bertelli et al, 2002). The
largest of these studies, which examined exemestane treatment in
patients who had failed on nonsteroidal AIs, found that 6.6% of
patients achieved an objective response and 17.4% prolonged
disease stabilisation (X24 weeks), which translates to a 24% total
clinical benefit rate (Lønning et al, 2000).
SELECTION OF THE OPTIMAL SEQUENCE OF AIs
If sequential application of AIs enables prolonged hormonal
treatment, in which order should these agents be given? The main
choice would appear to be whether to give a steroidal AI before a
nonsteroidal AI, or vice versa. As yet, clear clinical differences
between these two types have not emerged, nor is it known
whether their efficacy varies in different patient groups. There
may, however, be differences in side effect profiles between the
steroidal and nonsteroidal AIs, which may become clearer with
further clinical trial results. The main adverse events are hot
flushes, gastrointestinal (e.g. nausea and vomiting) and musculo-
skeletal events. In addition, effects have been reported on bone
density, lipid levels and thromboembolic events with hormonal
treatments. In the ATAC trial, there was a significantly lower
incidence of hot flushes, vaginal bleeding and discharge and
venous thromboembolism with anastrozole than tamoxifen, but
anastrozole was associated with more musculoskeletal symptoms
and fractures (ATAC Trialists Group, 2002). In addition, letrozole
has been associated with an increase in bone-resorption markers
in plasma and urine (Heshmati et al, 2002). By contrast, early
results from animal models and postmenopausal volunteers
suggest the steroidal AI, exemestane, may have a bone-sparing
effect compared with nonsteroidal agents (Goss et al, 2001, 2003b).
There is also evidence that exemestane does not adversely affect
blood lipids (Goss et al, 2001; Markopoulos et al, 2003), whereas
this may not be the case with the nonsteroidal AIs (Elisaf et al,
2001). More discussion of effects on bone and lipids is presented
elsewhere in the supplement.
The current practice is to use anastrozole or letrozole before
exemestane. This is based on the magnitude of the available
database and clinical experience with anastrozole and letrozole
compared with exemestane. Some evidence, however, suggests that
the opposite sequence is equally valid.
Steroidal AI followed by nonsteroidal AIs
The GONO (Gruppo Oncologico Nord Ovest) MIG-8 trial was
designed to assess treatment with different AI sequences in
postmenopausal patients with oestrogen receptor-positive or
-unknown advanced breast cancer. This is a prospective, non-
randomised study where patients not previously treated with AIs
received exemestane first, and were crossed over to a nonsteroidal
AI (anastrozole or letrozole) at the time of progression. Patients
with previous exposure to AIs received the alternative AI after
entering the study (exemestane for patients pretreated with a
nonsteroidal AI; letrozole or anastrozole for patients pretreated
with a steroidal AI: Figure 2). Preliminary results have been
reported on 10 patients evaluable for the sequence exemestane
followed by a nonsteroidal AI, with a clinical benefit rate (objective
responsesþstable disease X24 weeks) of 40% (Bertelli et al, 2002).
Harper-Wynne and Coombes reported on a group of patients
(n¼21) who had received the steroidal AI formestane and were
treated with anastrozole (Harper-Wynne and Coombes, 1999).
Overall, 62% of the patients stabilised on anastrozole. When only
those who had responded to formestane (n¼12) are considered,
78% achieved further stable disease on anastrozole (Harper-
Wynne and Coombes, 1999).
Nonsteroidal AIs followed by steroidal AI
The other AI sequence assessed in the GONO-MIG-8 trial was
exemestane following treatment with a nonsteroidal AI (letrozole
or anastrozole). At the first data report, clinical benefit was
obtained by 25% among 24 women in this group (Bertelli et al,
2002). This is similar to a clinical benefit rate of 20.4% reported by
Figure 1 Structural differences between the aromatase inhibitors.
Figure 2 GONO (Gruppo Oncologico Nord Ovest) MIG8 trial: study
design.
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of third-generation nonsteroidal AIs. The median duration of
clinical benefit was 37 weeks. Interestingly, exemestane was also
associated with responses in patients who had not responded to
prior hormone therapy (Lønning et al, 2000).
Carlini et al (2001) conducted a retrospective study on patients
receiving formestane after anastrozole or letrozole (n¼20).
The clinical benefit rate was 55%, with a median duration of
15 months.
Ongoing trials
There are several large trials currently in progress or planned
which should throw more light on whether there is an optimal
sequence for AI therapy. These include trials of:
  formestane followed by exemestane or anastrozole (SAINT);
  exemestane followed by anastrozole or vice versa (GEICAM
2001-03, GONO-MIG-8);
  nonsteroidal AIs followed by fulvestrant or exemestane in
patients failing nonsteroidal AIs (SOFEA).
Trials in progress include the NCIC MA27 and the SOFEA trials.
NCIC MA27 is a randomised phase III trial comparing exemestane
(with or without celecoxib) with anastrozole (with or without
celecoxib) for 5 years in preventing cancer recurrence in
postmenopausal women following surgery for primary breast
cancer. The study aims to recruit 6800 women. The SOFEA trial
is comparing fulvestrant with or without anastrozole versus
exemestane in 750 patients failing nonsteroidal AIs.
Other considerations
The impact of new agents, such as fulvestrant, on drug sequencing
will also need to be considered. Preliminary results from studies of
fulvestrant after progression on tamoxifen and anastrozole
reported a clinical benefit rate of 34–50%. Another study has
examined fulvestrant in women who had progressed on tamoxifen
and an AI (Perey et al, 2002). Of 20 patients who had progressed
after tamoxifen and a nonsteroidal AI, two showed a partial
response and five had stable disease for X24 weeks, which
represents a clinical benefit rate of 41%. An open, parallel-group
trial compared fulvestrant and anastrozole in postmenopausal
women with advanced breast cancer progressing after prior
endocrine treatment (Howell et al, 2002). Clinical benefit rates
were 44.6% for fulvestrant and 45.0% for anastrozole, median time
to progression was 5.5 months for fulvestrant and 5.1 months for
anastrozole. Similar results were reported in another trial of the
same design (Osborne et al, 2002).
CONCLUSIONS
Current evidence suggests that there is clinical utility in using
antiaromatase agents in sequence (steroidal inactivators after
nonsteroidal inhibitors, or vice versa). In other words, antiar-
omatase drugs of the two types can be used at different times to
prolong disease control, before changing to other, less tolerable
treatments (such as progestins or chemotherapy). The traditional
sequence of hormone therapy, which is to say, adjuvant tamoxifen
followed by an AI as first-line therapy at relapse and then
progestins as second line could therefore change to adjuvant
tamoxifen followed by an AI as first-line therapy at relapse and
then another AI as second line and finally, progestins as third-line
therapy. The above sequence is likely to change further based on
the results of recent and ongoing adjuvant trials (e.g. ATAC, MA-
17, BIG 1-98, ARNO, IES, NSABP B33, TEAM), which may result in
an increased number of patients exposed to AIs in the adjuvant
setting. The choice of first- and subsequent-line hormone therapy
for advanced disease will be based on the treatment history of the
patient, on the (limited) data reported above on noncross
resistance, and on a balance of the expected benefits and toxicities
with the agent of choice.
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